U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: Use of mRNA tests for human papillomavirus (HPV) [Internet]. 2nd edition. Geneva: World Health Organization; 2021.

Cover of WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention

WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: Use of mRNA tests for human papillomavirus (HPV) [Internet]. 2nd edition.

Show details

References

1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021:71:209–49. doi:10.3322/caac.21660. [PubMed: 33538338] [CrossRef]
2.
Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2020 (https://www​.who.int/publications​/i/item/9789240014107).
3.
Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 90. Lyon: International Agency for Research on Cancer; 2007 (https:​//publications​.iarc.fr/Book-And-Report-Series​/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans​/Human-Papillomaviruses-2007).
4.
de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70. doi:10.1002/ijc.30716. [PMC free article: PMC5520228] [PubMed: 28369882] [CrossRef]
5.
Comprehensive cervical cancer control: a guide to essential practice, second edition. Geneva: World Health Organization; 2014 (https://www​.who.int/reproductivehealth​/publications​/cancers/cervical-cancer-guide/en/). [PubMed: 25642554]
6.
Clarke MA, Gradissimo A, Schiffman M, Lam J, Sollecito CC, Fetterman B, et al. Human papillomavirus DNA methylation as a biomarker for cervical precancer: consistency across 12 genotypes and potential impact on management of HPV-positive women. Clin Cancer Res. 2018;24(9):2194–202. doi:10.1158/1078-0432.CCR-17-3251. [PMC free article: PMC5932258] [PubMed: 29420222] [CrossRef]
7.
Hu L, Bell D, Antani S, Xue Z, Yu K, Horning MP, et al. An observational study of deep learning and automated evaluation of cervical images for cancer screening. J Natl Cancer Inst. 2019;111(9):923–32. doi:10.1093/jnci/djy225. [PMC free article: PMC6748814] [PubMed: 30629194] [CrossRef]
8.
Lie AK, Kristensen G. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma. Expert Rev Mol Diagn. 2008;8(4):405–15. doi:10.1586/14737159.8.4.405. [PubMed: 18598223] [CrossRef]
9.
Sorbye SW, Fismen S, Gutteberg TJ, Mortensen ES, Skjeldestad FE. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study. BMJ Open. 2016;6(8):e011981. doi:10.1136/bmjopen-2016-011981. [PMC free article: PMC4985920] [PubMed: 27515759] [CrossRef]
10.
Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2536–45. doi:10.1158/1055-9965.EPI-08-0306. [PMC free article: PMC2900792] [PubMed: 18842994] [CrossRef]
11.
WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva: World Health Organization; 2013 (https://www​.who.int/reproductivehealth​/publications​/cancers/screening​_and_treatment​_of_precancerous_lesions/en/). [PubMed: 24716265]
12.
WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization; 2021 (https://www​.who.int/publications​/i/item/9789240030824). [PubMed: 34404156]
13.
International Agency for Research on Cancer. IARC handbooks of cancer prevention: cervical cancer screening, Vol. 18. Lyon, France: IARC Press; 2021 (in press; will be available at: https://handbooks​.iarc​.fr/publications/index.php).
14.
Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Giorgi-Rossi P, et al. The IARC perspective on cervical cancer screening. Special report. N Engl J Med. 2021;385:1908–18. doi:10.1056/NEJMsr2030640. [PubMed: 34758259] [CrossRef]
15.
Comprehensive cervical cancer control: a guide to essential practice, second edition. Geneva: World Health Organization; 2014 (https://www​.who.int/reproductivehealth​/publications​/cancers/cervical-cancer-guide/en/). [PubMed: 25642554]
16.
WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. Geneva: World Health Organization; 2019 (https://www​.who.int/publications​/i/item/9789241550598). [PubMed: 31661202]
17.
Introducing and scaling up testing for human papillomavirus as part of a comprehensive programme for prevention and control of cervical cancer: a step-by-step guide. Geneva: World Health Organization: 2020 (https://www​.who.int/publications-detail-redirect​/9789240015166).
18.
WHO handbook for guideline development, second edition. Geneva: World Health Organization; 2014 (https://apps​.who.int​/iris/handle/10665/145714).
19.
Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE handbook: handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. GRADEpro; updated October 2013 (https://gdt​.gradepro​.org/app/handbook/handbook.html).
20.
Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration; 2021 (https://training​.cochrane.org/handbook).
21.
Arbyn M, Simon M, Peeters E, Meijer CJLM, Berkhof J, Cuschieri K, et al. 2020 List of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect. 2021;27(8):1083–95. doi:10.1016/j.cmi.2021.04.031. [PubMed: 33975008] [CrossRef]
22.
Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):591–603. doi:10.1016/S0140-6736(20)30157-4. [PMC free article: PMC7043006] [PubMed: 32007142] [CrossRef]
23.
Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575–90. doi:10.1016/S0140-6736(20)30068-4. [PMC free article: PMC7043009] [PubMed: 32007141] [CrossRef]
24.
Burger EA, Smith MA, Killen J, Sy S, Simms KT, Canfell K, Kim JJ. Projected time to elimination of cervical cancer in the USA: a comparative modelling study. Lancet Public Health. 2020. 5(4):e213–e222. doi:10.1016/S2468-2667(20)30006-2. [PMC free article: PMC8715100] [PubMed: 32057315] [CrossRef]
25.
Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JML, Saville M, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2018;4(1):e19–e27. doi:10.1016/S2468-2667(18)30183-X. [PubMed: 30291040] [CrossRef]
26.
Kitchener HC, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess. 2014;18(23):1–196. doi:10.3310/hta18230. [PMC free article: PMC4781243] [PubMed: 24762804] [CrossRef]
27.
Lew J-B, Simms K, Smith M, Lewis H, Neal H, Canfell K. Effectiveness modelling and economic evaluation of primary HPV screening for cervical cancer prevention in New Zealand. PLoS ONE. 2016;11(5):e0151619. doi:10.1371/journal.pone.0151619. [PMC free article: PMC4871332] [PubMed: 27187495] [CrossRef]
28.
Lew J-B, Simms KT, Smith MA, Hall M, Kang YJ, Xu XM, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health. 2017;2(2):e96–e107. doi:10.1016/S2468-2667(17)30007-5. [PubMed: 29253402] [CrossRef]
29.
Shi JF, Canfell K, Lew JB, Zhao F-H, Legood R, Ning Y, et al. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer. 2011;11:239. doi:10.1186/1471-2407-11-239. [PMC free article: PMC3141766] [PubMed: 21668946] [CrossRef]
30.
Simms KT, Steinberg J, Caruana M, Smith MA, Lew J-B, Soerjomataram I, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study. Lancet Oncol. 2019;20:394–407. doi:10.1016/S1470-2045(18)30836-2. [PubMed: 30795950] [CrossRef]
31.
WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Web Annex A. Syntheses of evidence. Geneva: World Health Organization; 2021 (https://apps​.who.int​/iris/bitstream/handle​/10665/342366/9789240030886-eng.pdf).
32.
Pfadenhauer LM, Gerhardus A, Mozygemba K, Lysdahl KB, Booth A, Hofmann B, et al. Making sense of complexity in context and implementation: the context and implementation of complex interventions (CICI) framework. Implement Sci. 2017;12(1):21. doi:10.1186/s13012-017-0552-5. [PMC free article: PMC5312531] [PubMed: 28202031] [CrossRef]
33.
Vogel J, Dowswell T, Lewin S, Bonet M, Hampson L, Kellie F, et al. Developing and applying a “living guidelines” approach to WHO recommendations on maternal and perinatal health. BMJ global health. 2019;4(4). doi:10.1136/bmjgh-2019-001683. [PMC free article: PMC6703290] [PubMed: 31478014] [CrossRef]
© World Health Organization 2021.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Bookshelf ID: NBK576604

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.7M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...